<p><a href="http://us.rd.yahoo.com/dailynews/rss/business/*http://news.yahoo.com/s/nm/20051102/bs_nm/johnsonjohnson_guidant_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20051102/2005_11_02t104742_450x327_us_johnsonjohnson_guidan t.jpg?x=130&amp;y=94&amp;sig=kWXf2RMK86jQnKPZ0V3I7 A--" align="left" height="94" width="130" alt="Ronald Dollens, President and Chief Executive Officer of Guidant Corp. is seen at the Reuters Health Summit in New York, November 20, 2003. Johnson and Johnson on Wednesday said it may not complete its $25.4 billion purchase of Guidant, saying the recall of products at the medical device maker had hurt the value of the company. (Mike Segar/Reuters)" border="0" /></a>Reuters - Johnson &amp; Johnson's
$25.4 billion acquisition of troubled heart device
maker Guidant Corp. , the largest U.S. health care deal
in history, may find its final resolution in court, legal
experts said on Wednesday.</p><br clear=all>

View the entire article: J&J, Guidant battle seen ending in court (Reuters)